These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11384089)

  • 1. Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer.
    Leonard RC
    Br J Cancer; 2001 Jun; 84(11):1437-42. PubMed ID: 11384089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
    Wagstaff AJ; Ibbotson T; Goa KL
    Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
    Sternberg CN; Reichardt P; Holland M
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S4-15. PubMed ID: 15341878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moving forward with capecitabine: a glimpse of the future.
    Biganzoli L; Martin M; Twelves C
    Oncologist; 2002; 7 Suppl 6():29-35. PubMed ID: 12454317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
    Aprile G; Mazzer M; Moroso S; Puglisi F
    Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
    J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of capecitabine in first-line treatment for patients with metastatic breast cancer.
    Gelmon K; Chan A; Harbeck N
    Oncologist; 2006; 11 Suppl 1():42-51. PubMed ID: 16971739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.
    Talbot DC; Moiseyenko V; Van Belle S; O'Reilly SM; Alba Conejo E; Ackland S; Eisenberg P; Melnychuk D; Pienkowski T; Burger HU; Laws S; Osterwalder B
    Br J Cancer; 2002 May; 86(9):1367-72. PubMed ID: 11986765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer.
    Blum JL
    Oncologist; 2001; 6(1):56-64. PubMed ID: 11161228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
    Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
    Oshaughnessy JA; Blum J; Moiseyenko V; Jones SE; Miles D; Bell D; Rosso R; Mauriac L; Osterwalder B; Burger HU; Laws S
    Ann Oncol; 2001 Sep; 12(9):1247-54. PubMed ID: 11697835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
    Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
    J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?
    Seidman AD; O'Shaughnessy J; Misset JL
    Oncologist; 2002; 7 Suppl 6():20-8. PubMed ID: 12454316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer.
    Wardley A
    Oncologist; 2006; 11 Suppl 1():20-6. PubMed ID: 16971736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of capecitabine in gastric cancer.
    Comella P; Franco L; Casaretti R; de Portu S; Menditto E
    Pharmacotherapy; 2009 Mar; 29(3):318-30. PubMed ID: 19249950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.